New Search Results, from Technorati and Ingboo

Technorati and Ingboo have partnered together to provide an all new kind of subscription experience for Technorati content, including search results. Look for a blue Ingboo icon for a full range of subscription options.

Feeds are also available for:

Hottest Blogosphere Posts

Latest Original Articles from Technorati

The Technorati Blog

We also have channel feeds, writer feeds, and tag feeds, which can be found on their respective pages.



Top 25 DTC Marketers of the Year Announced for 2010

The Top 25 Marketers of the Year Awards are sponsored by PARADE magazine, in conjunction with the DTC National Conference, April 7-9, 2010 at the J.W. Marriott Hotel in Washington D.C.

Read the full story at http://www.prweb.com/releases/2010/02/prweb3600414.htm


Symfo announces that AstraZeneca has successfully completed a large-scale project using one of its ediary solutions

Today Symfo, a leading provider of handheld electronic patient diary (EPD) products for clinical trials, announces that AstraZeneca Farmaceutica SA (Spain) has successfully completed a project using the SymPro (Symfo Patient Reported Outcome Diary) involving more than 8,500 patients, 3,000 sites, and 1,300,000 downloaded data elements. This project was part of a 12-month multi-centre international post-marketing project.

Read the full story at http://www.prweb.com/releases/2004/09/prweb159433.htm


SCIREX Appoints Robert R. Allen, M.D., as Executive Officer, Science and Medicine

SCIREX Corporation announced today that Robert R. Allen, M.D., has been appointed Executive Officer, Science and Medicine, Office of the President, Clinical Site Operations. In his new role as the CSO divisionÂ’s chief scientist he will be responsible for the scientific and medical oversight of studies conducted at SCIREXÂ’s clinical research sites…

Read the full story at http://www.prweb.com/releases/2005/07/prweb257131.htm


Cross-Functional Skills the Key to Weathering an Uncertain Pharmaceutical Industry Job Market, Survey Finds

Pharmaceutical workers without cross-disciplinary skills and training are vulnerable; women, minorities, younger workers note disparity in earnings.

Read the full story at http://www.prweb.com/releases/2006/03/prweb358573.htm


Healthcare Packaging and Packaging World To Produce Pharmaceutical Packaging Forum 2008

Session topics at the March 12, 2008 Pharmaceutical Packaging Forum include the challenges of pharmaceutical package innovation; overall equipment effectiveness (OEE); contract packaging and anti-counterfeiting strategies.

Read the full story at http://www.prweb.com/releases/2007/10/prweb559478.htm


NETPLUS MARKETING SELECTS UNITED VIRTUALITIES FOR
ASTRAZENECA ONLINE ADVERTISING CAMPAIGN Campaign Marks Pharmaceutical Industry’s First Use of “Shoshkele” Technology

NetPlus Marketing, Inc., an online advertising, email and marketing agency, announces the debut of the Web’s first Shoshkele™ advertising campaign for the pharmaceutical industry.

Read the full story at http://www.prweb.com/releases/2001/10/prweb29415.htm


Euroscreen Licenses CCR5 Patent Rights to AstraZeneca

Euroscreen S.A. has completed a license agreement with AstraZeneca UK Ltd, for access to its worldwide portfolio of CCR5 patent rights. Financial details of the agreement were not disclosed.

Read the full story at http://www.prweb.com/releases/2008/03/prweb674774.htm


Pharmaceutical Sales Certification and E-Learning on the Increase for 2006

Pharmaceutical sales certification, education and training — Outlook for 2006.

Read the full story at http://www.prweb.com/releases/2006/01/prweb335694.htm


Dynavax Receives Milestone from AstraZeneca : Novel Asthma/COPD Drug Candidate Nominated for Clinical Development

Dynavax Technologies, Inc. (NASDAQ:DVAX) today announced receipt of a $4.5 million milestone payment from its partner AstraZeneca AB for the nomination of candidate drug AZD1419 for the treatment of asthma and chronic obstructive pulmonary disease (COPD). As part of this potential $136 million development and commercialization collaboration, AstraZeneca and Dynavax have initiated Investigational New Drug (IND) enabling studies with AZD1419 and plan to begin phase 1 clinical development in 2009.

Read the full story at http://www.prweb.com/releases/dynavax_technologies/clinical_development/prweb1368074.htm


WellDoc and AstraZeneca Collaborate to Develop Asthma Management Solution : Collaboration will create patient-centric, mobile- and Web-based tools to help asthma sufferers

WellDoc Communications, Inc., a healthcare company that develops technology solutions to help improve chronic disease management, is partnering with AstraZeneca Pharmaceuticals LP to educate patients about the importance of their medicine in asthma control. As part of its patient support program AstraZeneca’s respiratory franchise will utilize WellDoc’s web- and mobile-based asthma solution, including virtual messenger, air quality and pollen count alerts as well as online patient support tools, allowing patients to manage their condition, consistent with the treatment plan of the patient’s physician, throughout their day and in real time.

Read the full story at http://www.prweb.com/releases/welldoc/patient/prweb1341024.htm


My Medicare Matters Campaign to Award Grants for New Initiatives to Reach Low-Income Seniors

Ongoing community-based education and outreach for Medicare Part D. My Medicare Matters, which is sponsored by the National Council on Aging (NCOA) and supported through a grant from AstraZeneca Pharmaceuticals, announced today its targeted community-based education and outreach initiatives in 2007 in support of Medicare Part-D, which will include a project designed to identify and pilot innovative strategies that can help find and reach low-income seniors who may be eligible for Medicare Extra Help and other prescription savings programs.

Read the full story at http://www.prweb.com/releases/2006/12/prweb488321.htm


My Medicare Matters Turns its Focus to Low-Income Seniors

Recognizing that more than three million people with limited income and resources have not yet applied for the Medicare Part D prescription plan, My Medicare Matters announced its donation of technology to community organizations located within the top 100 counties where Center for Medicare Services (CMS) estimates that the remaining Medicare beneficiaries with limited resources reside.

Read the full story at http://www.prweb.com/releases/2006/12/prweb490903.htm


v-Fluence Online Health Communications, Marketing Expands with Key Hire, New Clients

v-Fluence Interactive is pleased to announce the hiring of Kirsten Shae Johnson to complement the company’s growing base of clients and research in its pharmaceutical and healthcare practice area.

Read the full story at http://www.prweb.com/releases/Online_Analytics/Pharmaceutical_Healthcare/prweb976694.htm


AstraZeneca Maintains European Product Monopoly for Arimidex (Anastrozole) with the Grant of a Paediatric Extension

GenericsWeb analyses the patent landscape surrounding Anastrozole, highlighting the need for comprehensive patent information in the development of launch strategies for generic products to minimise the risk of litigation.

Read the full story at http://www.prweb.com/releases/2010/09/prweb4453654.htm


BIOWISDOM AND LINGUAMATICS TO PROVIDE AN ONTOLOGY AND NLP-BASED TEXT MINING APPLICATION TO ASTRAZENECA.

BIOWISDOM AND LINGUAMATICS TO PROVIDE AN ONTOLOGY AND NLP-BASED TEXT MINING APPLICATION TO ASTRAZENECA.

Read the full story at http://www.prweb.com/releases/2003/10/prweb86273.htm


AstraZeneca and Food University™ Team Up for Healthy Eating

New Partnership Kicks Off During National Nutrition Month, Bringing Simple, Low-Cholesterol Recipes Directly to Your Kitchen

Read the full story at http://www.prweb.com/releases/2011/03/prweb5162274.htm


Melior Enters Research Collaboration with AstraZeneca

Melior Discovery, Inc. announced today that it has signed an agreement with AstraZeneca PLC under which Melior’s in-vivo theraTRACE® indications discovery platform will be used to evaluate the therapeutic activity of selected AstraZeneca compounds.

Read the full story at http://www.prweb.com/releases/melior/astrazeneca/prweb1226754.htm


AstraZeneca’s Brennan, Congressman Gephardt Speak on the Importance of Manufacturing

Outsourcing manufacturing has its value, say AstraZeneca CEO David Brennan and former House Majority Leader Dick Gephardt, but can never replace the importance of in-house manufacturing expertise to a company’s ability to innovate and survive.

Read the full story at http://www.prweb.com/releases/2009/04/prweb2342114.htm


AstraZeneca Pays $520 Million to Settle Seroquel Whistleblower Claims

Kenney & McCafferty Represent Whistleblower Dr. Stefan Kruszewski

Read the full story at http://www.prweb.com/releases/2010/04/prweb3937374.htm


Handa Pharmaceuticals Announces Tentative Approval of its First-to-File ANDA for AstraZeneca’s SEROQUEL XR®

Handa Pharmaceuticals, LLC (“Handa”), a specialty pharmaceutical company based in Fremont, California, today announced that the U.S. Food and Drug Administration (“FDA”) has granted tentative approval of the Company’s Abbreviated New Drug Application (“ANDA”) for Quetiapine Fumarate Extended-Release Tablets, 50 mg., 150 mg., 200 mg., 300 mg., and 400 mg., a generic version of AstraZeneca’s SEROQUEL XR®.

Read the full story at http://www.prweb.com/releases/2010/12/prweb4890534.htm


Freedland Russo Announces $520 Million Settlement Against AstraZeneca

Freedland Russo is pleased that Eric Holder, U.S. Attorney General, announced the $520 million dollar settlement of a lawsuit filed against AstraZeneca (Civil Action #04-3479; US District Court, Eastern District of Pennsylvania).

Read the full story at http://www.prweb.com/releases/Freedland_Russo/AstraZeneca_settlement/prweb3934034.htm


Astra Zeneca Featured in Australia’s Best – Top Industry Publication Highlights the Australian Company as a Shining Example in the Industry

Australia-based Astra Zeneca has received a rather large pat on the back in the form of the popular series of magazines, ‘Australia’s Best’. The company has been included in the July edition of Australia’s Best Manufacturing.

Read the full story at http://www.prweb.com/releases/2008/07/prweb1151134.htm


ExpressOn BioSystems and AstraZeneca collaborate on target validation

ExpressOn BioSystems Ltd and AstraZeneca have recently completed a contract to design small inhibitory RNA molecules (siRNAs) using ExpressOn’s ACCESSarray technology platform.

Read the full story at http://www.prweb.com/releases/2003/08/prweb75054.htm


Angel.com Launches Caller First IVR Solutions with AstraZeneca

Angel.com has deployed a number of Caller First focused inbound and outbound IVR solutions for AstraZeneca, one of the largest pharmaceutical companies in the world. This has resulted in a reduction of AstraZeneca’s cost per lead, a more cohesive customer experience, more satisfied customers and greater efficiency of their agent engagement.

Read the full story at http://www.prweb.com/releases/angelivr/astrazeneca/prweb3552844.htm


Solcara PressBureau Wins AstraZeneca Contract

Solcara today announced that pharmaceutical giant AstraZeneca will be implementing the marketing leading press office solution, Solcara PressBureau.

Read the full story at http://www.prweb.com/releases/2006/07/prweb405795.htm


Torrent to sell stake to AstraZeneca?
A possible tie-up between city-based Torrent Pharmaceutical and London-based AstraZeneca over outsourcing and co-marketing patented drugs in developing markets has led to a strong speculation of a stake sale to the UK giant.

Justices back pharmaceuticals
The Supreme Court ruled a Calif. county can’t sue a group of drugmakers, including Pfizer , Merck , AstraZeneca , GlaxoSmithKline and Bristol-Myers Squibb , for not extending pricing pacts made with the federal gov’t to other hospital operators that receive federal funds.

Drugs group settles US tax row
ASTRAZENECA, THE Anglo-Swedish pharmaceuticals group, has agreed to pay the US Internal Revenue Service $1.1 billion to settle two long-running disputes, clearing the way to greater predictability in its tax planning on both sides of the Atlantic.

AstraZeneca settles US tax dispute, raises earnings
Anglo-Swedish pharmaceuticals giant AstraZeneca said Monday it had settled a tax dispute with US authorities by agreeing on a net payment of $1.1 billion (783 million euros).

Filed under: Uncategorized

Like this post? Subscribe to my RSS feed and get loads more!